Bayerisches Start-Up realisiert weltweit führende Hochleistungstechnik für E-Mobilität und Industrie
Kaufbeuren (ots) - Die Hochtechnologie der dynamic E flow GmbH bildet eine effektive Grundlage für die ...
Der Miner von Kryptowährungen setzt auf ökologische Effizienz und baut seine Rechenzentren direkt in bereits ...
München (ots) - Ab sofort verstärken Christiane Ritter, Tim Jungblut und Sebastian Schütze das Team von ...
Eysins, Switzerland (ots) - Following the full registration of its product range by the Chinese FDA last April, Biosafe is gearing up its activities in the People's Republic of China with a major expansion of its Shanghai-based operations, including staffing and facilities consolidation. Such expansion will enable Biosafe to support the many new developments in China within the Cord Blood Banking, Regenerative Medicine and Bioprocessing markets where the Group holds leadership.
To mark this significant business extension, Biosafe is today holding an official celebration event at the Grand Hyatt Hotel Shanghai, with a conference on stem cell therapy that will include a keynote presentation from Dr. Joanne Kurtzberg (Director, Pediatric Blood and Marrow Transplant Program, Duke University, USA).
Olivier Waridel, CEO of the Biosafe Group commented: "This expansion of our China operations underlines the commitment of Biosafe to cooperate with the Chinese cell therapy community, by working more closely with our clients and scientific partners in the People's Republic of China. Biosafe looks forward to further developing close relationships with them and is enthusiastic about jointly supporting their efforts".
About the Biosafe Group
Founded in 1997 the Biosafe Group is active in the design, manufacture and marketing of automated cell processing systems. Headquartered in Switzerland and privately-owned, the Biosafe Group operates through regional subsidiaries (Geneva, Houston, Hong-Kong, Shanghai and São Paulo) and is present in more than 50 countries, either directly or through distributors.